Last reviewed · How we verify

Doxycycline (Oracea) — Competitive Intelligence Brief

Doxycycline (Oracea) (Doxycycline (Oracea)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic (anti-inflammatory formulation). Area: Dermatology.

marketed Tetracycline antibiotic (anti-inflammatory formulation) Matrix metalloproteinases (MMPs); 30S ribosomal subunit Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Doxycycline (Oracea) (Doxycycline (Oracea)) — LEO Pharma. Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and at sub-antimicrobial doses in Oracea formulation, it reduces matrix metalloproteinase activity to decrease inflammation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Doxycycline (Oracea) TARGET Doxycycline (Oracea) LEO Pharma marketed Tetracycline antibiotic (anti-inflammatory formulation) Matrix metalloproteinases (MMPs); 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic (anti-inflammatory formulation) class)

  1. LEO Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Doxycycline (Oracea) — Competitive Intelligence Brief. https://druglandscape.com/ci/doxycycline-oracea. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: